Autopsy report · NCT04966676

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 7 months before it started.
Ran for about 3 years 1 month before it stopped.
5 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: University Health Network, Toronto
Sponsor type: University, hospital or other
Conditions: Non Small Cell Lung Cancer
Interventions: cfDNA blood test; Nivolumab; Ipilimumab; Platinum-based Chemotherapy
Participants: 5
Sites: 1
Countries: Canada

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.